Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.

Burnight ER, Giacalone JC, Cooke JA, Thompson JR, Bohrer LR, Chirco KR, Drack AV, Fingert JH, Worthington KS, Wiley LA, Mullins RF, Stone EM, Tucker BA.

Prog Retin Eye Res. 2018 Jul;65:28-49. doi: 10.1016/j.preteyeres.2018.03.003. Epub 2018 Mar 22. Review.

PMID:
29578069
2.

Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases.

Cai B, Sun S, Li Z, Zhang X, Ke Y, Yang J, Li X.

Hum Genet. 2018 Sep;137(9):679-688. doi: 10.1007/s00439-018-1933-9. Epub 2018 Sep 10. Review.

PMID:
30203114
3.

Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.

Burnight ER, Gupta M, Wiley LA, Anfinson KR, Tran A, Triboulet R, Hoffmann JM, Klaahsen DL, Andorf JL, Jiao C, Sohn EH, Adur MK, Ross JW, Mullins RF, Daley GQ, Schlaeger TM, Stone EM, Tucker BA.

Mol Ther. 2017 Sep 6;25(9):1999-2013. doi: 10.1016/j.ymthe.2017.05.015. Epub 2017 Jun 12.

4.

Potential of Gene Editing and Induced Pluripotent Stem Cells (iPSCs) in Treatment of Retinal Diseases.

Chuang K, Fields MA, Del Priore LV.

Yale J Biol Med. 2017 Dec 19;90(4):635-642. eCollection 2017 Dec. Review.

5.

Hot News: Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.

Soriano V.

AIDS Rev. 2017 Oct-Dec;19(3):167-172.

PMID:
29019352
6.

The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases.

Peddle CF, MacLaren RE.

Yale J Biol Med. 2017 Dec 19;90(4):533-541. eCollection 2017 Dec. Review.

7.

Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.

Lyu C, Shen J, Wang R, Gu H, Zhang J, Xue F, Liu X, Liu W, Fu R, Zhang L, Li H, Zhang X, Cheng T, Yang R, Zhang L.

Stem Cell Res Ther. 2018 Apr 6;9(1):92. doi: 10.1186/s13287-018-0839-8.

8.

Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases.

Wiley LA, Burnight ER, Songstad AE, Drack AV, Mullins RF, Stone EM, Tucker BA.

Prog Retin Eye Res. 2015 Jan;44:15-35. doi: 10.1016/j.preteyeres.2014.10.002. Epub 2014 Nov 4. Review.

PMID:
25448922
9.

CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.

Zhang X, Wang L, Liu M, Li D.

Sci China Life Sci. 2017 May;60(5):468-475. doi: 10.1007/s11427-017-9057-2. Epub 2017 Apr 20. Review.

PMID:
28534255
10.

Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.

Doetschman T, Georgieva T.

Circ Res. 2017 Mar 3;120(5):876-894. doi: 10.1161/CIRCRESAHA.116.309727. Review.

PMID:
28254804
11.

CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.

Zhang Y, Sastre D, Wang F.

Curr Stem Cell Res Ther. 2018;13(4):243-251. doi: 10.2174/1574888X13666180214124800. Review.

PMID:
29446747
12.

CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.

Kim EJ, Kang KH, Ju JH.

Korean J Intern Med. 2017 Jan;32(1):42-61. doi: 10.3904/kjim.2016.198. Epub 2017 Jan 1. Review.

13.

The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.

Ou Z, Niu X, He W, Chen Y, Song B, Xian Y, Fan D, Tang D, Sun X.

Sci Rep. 2016 Sep 1;6:32463. doi: 10.1038/srep32463.

14.

CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.

Wang HX, Li M, Lee CM, Chakraborty S, Kim HW, Bao G, Leong KW.

Chem Rev. 2017 Aug 9;117(15):9874-9906. doi: 10.1021/acs.chemrev.6b00799. Epub 2017 Jun 22. Review.

PMID:
28640612
15.

CRISPR/Cas9 for Human Genome Engineering and Disease Research.

Xiong X, Chen M, Lim WA, Zhao D, Qi LS.

Annu Rev Genomics Hum Genet. 2016 Aug 31;17:131-54. doi: 10.1146/annurev-genom-083115-022258. Epub 2016 May 23. Review.

PMID:
27216776
16.

The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models.

Shao M, Xu TR, Chen CS.

Dongwuxue Yanjiu. 2016 Jul 18;37(4):191-204. doi: 10.13918/j.issn.2095-8137.2016.4.191. Review.

17.

Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.

Ben Jehuda R, Shemer Y, Binah O.

Stem Cell Rev. 2018 Jun;14(3):323-336. doi: 10.1007/s12015-018-9811-3. Review.

PMID:
29623532
18.

Therapeutic Genome Editing and its Potential Enhancement through CRISPR Guide RNA and Cas9 Modifications.

Batzir NA, Tovin A, Hendel A.

Pediatr Endocrinol Rev. 2017 Jun;14(4):353-363. doi: 10.17458/per.vol14.2017.BTH.Therapeu. Review.

PMID:
28613045
19.

Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.

Kuruvilla J, Sasmita AO, Ling APK.

Neurol Sci. 2018 Nov;39(11):1827-1835. doi: 10.1007/s10072-018-3521-0. Epub 2018 Aug 3. Review.

PMID:
30076486
20.

CRISPR in the Retina: Evaluation of Future Potential.

Cho GY, Justus S, Sengillo JD, Tsang SH.

Adv Exp Med Biol. 2017;1016:147-155. doi: 10.1007/978-3-319-63904-8_8. Review.

PMID:
29130158

Supplemental Content

Support Center